TBC and COVID: an interplay between two infections.
Coinfection
LTBI
Mycobacterium tuberculosis
SARS-CoV-2
immunopathogenesis
Journal
Expert opinion on drug safety
ISSN: 1744-764X
Titre abrégé: Expert Opin Drug Saf
Pays: England
ID NLM: 101163027
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
medline:
22
5
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
In a historical era dominated by the SARS-CoV-2 pandemic, a fact of growing interest emerges regarding co-infection with With this review, we wanted to collect and analyze the latest scientific evidence concerning the main immunopathogenetic mechanisms shared by these two respiratory pathogens, with particular interest in the possible iatrogenic factors favoring coinfection and the need to define multidisciplinary and standardized screening tools aimed to identify coinfection early, ensuring the best clinical and therapeutic management. The existence of a direct immunopathogenetic link between COVID-19 and TB indirectly contributes to mutual morbidity and mortality. The identification and application of early and standardized screening tools aimed at the identification of this condition is essential, in addition to vaccine prevention.
Identifiants
pubmed: 37079022
doi: 10.1080/14740338.2023.2205638
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM